Table 6.
Causes of deviation from guidelines for every drug and diagnosis in %
|
Causes of deviation from guidelines from patient’s view | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| n | 69 | 8 | 15 | 8 | 4 | 15 | 53 | 12 | 21 |
|
Reason (in %) |
Anti-HT |
Metformin |
HF: βB |
HF: RAAS-I |
HF: AldoA |
AF: OAK |
CVD: statin |
CVD: antipltlt |
MCI: βB |
| I don’t know |
91.3 |
50.0 |
60.0 |
62.5 |
75.0 |
66.7 |
30.2 |
50.0 |
76.2 |
| I don’t need it |
2.9 |
25.0 |
26.7 |
37.5 |
25.0 |
|
45.3 |
25.0 |
9.5 |
| I don’t want it |
|
12.5 |
|
|
|
13.3 |
7.5 |
|
|
| Adverse drug event |
4.3 |
|
13.3 |
|
|
6.7 |
7.5 |
|
4.8 |
| Falsely discontinued |
1.4 |
12.5 |
|
|
|
13.3 |
9.4 |
25.0 |
9.5 |
|
Causes of deviation from guidelines from physician’s view | |||||||||
|
n |
69 |
8 |
15 |
8 |
4 |
15 |
53 |
12 |
21 |
|
Reason (in %) |
Anti-HT |
Metformin |
HF: βB |
HF: RAAS-I |
HF: AldoA |
AF: OAK |
CVD: statin |
CVD: PAI |
MCI: βB |
| Falsely not indicated GP |
78.3 |
37.5 |
80.0 |
62.5 |
50.0 |
33.3 |
56.6 |
33.3 |
52.4 |
| Falsely not indicated s/h |
8.7 |
12.5 |
6.7 |
25.0 |
25.0 |
6.7 |
7.5 |
8.3 |
23.8 |
| Noncompliance |
2.9 |
25.0 |
|
|
|
20.0 |
17.0 |
25.0 |
9.5 |
| Adverse drug event |
8.7 |
25.0 |
6.7 |
12.5 |
25.0 |
6.7 |
11.3 |
25.0 |
4.8 |
| Falsely discontinued |
1.4 |
|
6.7 |
|
|
6.7 |
3.8 |
|
|
| Contraindication |
|
|
|
|
|
26.7 |
|
8.3 |
9.5 |
| Avoidance of polypharmacy | 3.8 | ||||||||
Summation does not add up to 100% due to rounding error.
Anti-HT: antihypertensive medication (RAAS-inhibitor or thiazide or calcium channel blocker or β-blocker).
Metformin: metformin in diabetes mellitus type 2 patients.
HF = heart failure.
βB: beta adrenoceptor blocker.
RAAS-I: inhibitor of the renin-angiotensin-aldosterone system.
AldoA: aldosterone antagonist.
AF = atrial fibrillation.
OAK: oral anticoagulation.
CVD = cardiovascular disease.
PAI: platelet aggregation inhibitor (acetylsalicylic acid or clopidogrel/prasugrel).
MCI = myocardial infarction.